Contact Vaccitech

Thank you for your interest in Vaccitech and your enquiry about our ongoing clinical trials.

Please note that all information on ongoing or closed clinical trials run by Vaccitech, including eligibility criteria and contact information are posted on the https://clinicaltrials.gov/ website.

Chronic Hepatitis B:  Vaccitech is conducting a Phase 1 study to determine the safety and tolerability of different doses of a single dose therapeutic vaccination of ChAdOx1 HBV in healthy participants and in participants with chronic hepatitis B virus (CHB) infection who are virally suppressed with oral antiviral medication. This trial is recruiting in the UK. More information and trial site contact details can be found at: https://clinicaltrials.gov/ct2/show/NCT04297917.

Vaccitech is also conducting a Phase 1/2 study to determine the safety, tolerability, and immunogenicity of VTP-300 and MVA-HBV vaccines, with or without an anti-PD-1 antibody, in patients with chronic hepatitis B virus infection who are virally suppressed with oral anti-viral medication. This trial will recruit participants in South Korea, Taiwan, and the UK. More information and trial site contact details can be found at:  https://clinicaltrials.gov/ct2/show/NCT04778904

Low-grade cervical human papilloma virus (HPV) Lesions:  Vaccitech is conducting a Phase 1b/2 clinical trial to determine the safety and tolerability of different doses of VTP-200  plus MVA HPV vaccines in women with high-risk HPV.  This trial is recruiting in the UK and Europe.  More information and trial site contact details can be found at:  https://clinicaltrials.gov/ct2/show/NCT04607850

Non-small cell lung cancer:  There is a lung cancer trial that will be run by Cancer Research UK (CRUK) with VTP-600.  It is not yet open to enrol patients.  Information about the trial will soon be available at the following CRUK website:  https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-vaccine-chemotherapy-and-an-immunotherapy-for-non-small-cell-lung-cancer

If you would like to speak with someone about this trial or other lung cancer trials, please phone the CRUK Nurses Helpline on the following number:  0808 800 4040

Covid19:  For medical enquiries about the AstraZeneca Covid19 vaccine, AZD1222, please call AstraZeneca’s UK based Medical Information team at: 0800 783 0033.

General information regarding Vaccitech can be found on this website.

Following the implementation of GDPR legislation, Vaccitech will not retain any emails which contain personal information and therefore any email communication with Vaccitech will be permanently deleted from our email server.